Some coronavirus variants can resist antibody treatments, FDA tells clinicians

The FDA has revised its clinician resources on monoclonal antibody therapies for COVID-19 to include information on variants. 

The fact sheets, updated March 18, outline how certain variants may affect efficacy of the three antibody therapies with emergency use approval in the U.S.

Variants discussed in the fact sheets are:

  • B.1.1.7 (U.K. origin)
  • B.1.351 (South Africa origin)
  • P.1 (Brazil origin)
  • B.1.427/B.1.429 (California origin)
  • B.1.526 (New York origin)

"Some variants can cause resistance to one or more of the mAb therapies authorized to treat COVID-19," the FDA said. "Healthcare providers should consider the prevalence of mAb-resistant variants in their area, where data are available, when considering treatment options."

To learn more, click here.

More articles on patient safety and outcomes:

NYC Health + Hospitals aims to reduce unneccessary care with new guidelines
COVID-19 death risk 64% higher for UK variant, study suggests
10 top patient safety concerns for 2021, ranked by ECRI Institute

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars